CTRI/2022/08/045113已完成4 期
An Open Label, Prospective, Multicenter, Postmarketing Surveillance (Phase IV) Study to Evaluate the Safety, Tolerability, and Efficacy of Lemborexant in Adult Subjects (Age 18-65 Years) With Insomnia in India.
Eisai Pharmaceuticals India Pvt Ltd0 个研究点目标入组 110 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female aged 18 -65 years old (both inclusive) at the time of informed consent.
- •2. A clinical diagnosis of insomnia, as determined by the investigator
- •3. The decision to prescribe lemborexant for the patient has been made independently from the study participation.
排除标准
- •1. Currently enrolled in another clinical study
- •2. Previously discontinued lemborexant treatment for any reason
- •3. Previously participated in this study.
研究者
相似试验
已完成
4 期
Evaluation of safety of Effectiveness And Safety Of An Appetite Stimulating Tonic In Children.CTRI/2023/10/058301Abbott Healthcare Private Limited380
已完成
4 期
Post marketing surveillance study on patients referred for contrast enhancement MRI of various organs including brain, spinal cord, breast, liver and kidneyCTRI/2021/03/032302Vivere Imaging Private Limited100
尚未招募
4 期
Evaluation of Anti-Anginal Effectiveness of Trimetazidine 60 mg Once Daily in Stable Angina PatientsCTRI/2024/07/069720Abbott Healthcare Private Limited
尚未招募
4 期
Study to evaluate safety and effectiveness of injection for patients seeking treatment for Frozen ShoulderCTRI/2024/06/069688Abbott India Limited
已完成
4 期
To Study effectiveness and safety of Anti-malarial drug on uncomplicated falciparum malariaCTRI/2014/01/004286Ranbaxy Laboratories Ltd400